2022
P11.46.A Whole exome sequencing identifies novel SLIT2 mutations in primary CNS lymphoma
Kaulen L, Erson-Omay E, Henegariu O, Karschnia P, Huttner A, Günel M, Baehring J. P11.46.A Whole exome sequencing identifies novel SLIT2 mutations in primary CNS lymphoma. Neuro-Oncology 2022, 24: ii68-ii68. PMCID: PMC9443199, DOI: 10.1093/neuonc/noac174.235.Peer-Reviewed Original ResearchPrimary CNS lymphomaCNS lymphomaOverall survivalExtension cohortEpstein-Barr virus statusKaplan-Meier methodLog-rank testCBio Cancer Genomics PortalReporter luciferase assaysFree survivalShorter OSTumor DNA samplesPCNSL patientsClinical outcomesShorter PFSSomatic insertions/deletionsVirus statusFavorable outcomeLymphoid malignanciesClinical observationsTumor tissuePersonalized careCDKN2A lossCopy number alterationsCohort
2020
Associations of meningioma molecular subgroup and tumor recurrence
Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, Montejo JD, Zhao A, Sheth A, Tyrtova E, Özduman K, Iacoangeli F, Peyre M, Boetto J, Pease M, Avşar T, Huttner A, Bilguvar K, Kilic T, Pamir MN, Amankulor N, Kalamarides M, Erson-Omay EZ, Günel M, Moliterno J. Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology 2020, 23: 783-794. PMID: 33068421, PMCID: PMC8099468, DOI: 10.1093/neuonc/noaa226.Peer-Reviewed Original ResearchConceptsDivergent clinical coursesMolecular subgroupsClinical courseClinical outcomesProgression-free survivalExtent of resectionKaplan-Meier analysisLong-term outcomesLow-grade tumorsCox proportional hazardsDistinct clinical outcomesPostoperative radiationIndependent predictorsMale sexRecurrence rateSurveillance imagingTumor recurrencePrevious recurrencesClinical prognosticationKi-67Outcome dataAggressive subgroupRecurrenceElevated recurrenceProportional hazards
2019
HOUT-03. CLINICAL OUTCOMES OF PATIENTS WITH VESTIBULAR SCHWANNOMAS: THE RELEVANCE OF TUMOR SIZE AND RECURRENCE
Zhao A, Fomchenko E, Tyrtova E, Huttner A, Zhang Y, Fulbright R, Erson-Omay E, Jin L, Moliterno J. HOUT-03. CLINICAL OUTCOMES OF PATIENTS WITH VESTIBULAR SCHWANNOMAS: THE RELEVANCE OF TUMOR SIZE AND RECURRENCE. Neuro-Oncology 2019, 21: vi112-vi112. PMCID: PMC6846905, DOI: 10.1093/neuonc/noz175.468.Peer-Reviewed Original ResearchVestibular schwannomaSurgical resectionClinical outcomesTumor sizeLarge tumorsExact testPre-operative tumor sizeSignificant associationProgression-free survival timeMost vestibular schwannomasFacial nerve functionPost-operative complicationsBetter clinical outcomesLow recurrence rateClinical outcome dataBilateral vestibular schwannomasDifferent surgical approachesFisher's exact testSlow growth potentialIntra-tumoral hemorrhageWhole-exome sequencingNerve functionRecurrence rateVS tumorsSurgical approach